NEW YORK, Nov. 21, 2000 – Pyrosequencing of Uppsala, Sweden announced Tuesday it had sold its PSQ 96 DNA sequencing system to the Harvard Center for Cancer Prevention.
Harvard will use the system, which sells for $89,000 , to analyze genetic variations in sample populations and compare this information with known risk factors for colon cancer, breast cancer, and other diseases.
The PSQ 96 operates on a proprietary “sequencing-by-synthesis” technology, which uses a luciferase light-generating reaction to map sequences in minutes. Researchers can use it for rapid SNP analysis Tag sequencing.
" We are delighted that Harvard Center for Cancer Prevention has chosen our PSQ 96 System to advance their research in cancer and other important diseases," said Pyrosequencing CEO Erik Wallden. " Our instruments and reagents continue to gain broad acceptance among the world's leading academic institutions and we believe that our approach will be the new standard in applied genetic analysis."
Pyrosequencing has also sold its PSQ 96 to Sweden's Karolinska Institute, the National Institutes of Health, the National Cancer Center of Tokyo, and the University of California at Davis.